We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Valirx Plc | VAL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 1.52% | 3.35 | 15:18:31 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.30 | 3.30 | 3.35 | 3.35 | 3.30 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 10/4/2024 09:48 by jasonpugh Yes mr mark ecclestone. Is there any truth that you will be joining suzy at black cat bio to help her steal val assets? Sorry not steal. Will use a more precise definition..pickpock |
Posted at 05/4/2024 11:38 by porky9 @lucifier7OK for the purpose of entertainment please educate me as to why you think the business as it stands today is worth more than it’s £5m MCap? My reasoning why it isn’t: MCap was £2.25m in April 21 at its previous restructure yet back then was better positioned and had cash burn under £1.5m 201 is going nowhere, totally neglected and likely superseded, over 15 years old and needs reformulating and new patents, it’s handling a total disaster 301 same and off back of same tech and doing zero. 401 moved to another start up that is trying to get funding for itself to survive being a Phoenix business so little chance of any value there in next 12 months CLX - yes this has potential value I will put it at £1m top side. It needs at least another year dev on it and £400k more to try and position it. So Jam tomorrow for 2025 maybe but won’t be contributing to keep VAL alive short term Labs - what a bloody farce, zero paying customers, decision to buy a load of cell samples sitting in freezers from Imogen that couldn't make its business viable even with 32 staff at its height and the current BOD want to chuck more of your cash at it. I put lab assets at £500k top side if they could find a buyer. So that’s it, I calculate £1.5m of assets at best and a cash burn of £2.5m to feed a load of greedy directors to maintain lifestyles. As cash will likely run out July perhaps the BOD should award themselves a nice big bonus whilst they still have the cash. So please explain how you get a value to justify its current share price? I don’t see it. Even with a new BOD at a penny raise it’s a risk. It’s certainly in a worse place than it was in April 21. I put Share price should be in the region of 1.5p to 1.7p pre 1p Placing IMO |
Posted at 29/1/2024 10:52 by jasonpugh Newsflash. Adam Hargreaves has resigned from Valirx scientific advisory board.Q. Why isn’t the biggest shareholder by far calling for an EGM? A. Wanting val to go into administration so his company and Suzy company can steal the assets. Remember Val got them at over 40 times cheaper. Q. Why did suzy buy only £4K worth of shares at the placing? A. No need to answer this one 🤦a Q. In the video on q and a last year Stella Panu was asked why she had not purchased Val shares and her answer was valirx was uninvestable. Why did she say this? A. Because she was shorting it. 👍 lol 👇. DYOR |
Posted at 18/1/2024 12:54 by porky9 Also, if any of the perma bulls around would like to challenge me on my valuation comments I would welcome that if I have overlooked something? I seriously don’t see this business valued at anything remotely near the £7.35m the current value, the 5.5p Share Price – you are literally buying the “Emperor’Let me break it down: - 1. Inaphaea labs – This is now what this business is all about. Suzy’s pet project. So, you have a start up lab business eating cash led by directors that have NEVER built or scaled a business from ground up. The model is highly labour intensive. They have three scientists. Imogen at its height had over 36 staff and still couldn’t make it viable. Now they want to waste £600k of your cash expanding the Imogen Biobank and £200k on developing the lab brand – that’s half the cash raised in this lab!!! Yet they can’t make what they have pay? I will be interested to see what the three months contract they won was worth when they issue to results to the end of December, I suspect it was a token fee. As I see it, its going to take a heck of a lot of time and more cash to establish this lab and investors did not sign up for that, the BOD took them down this path. Most UK labs are loss making, the best in the market can only deliver up to a 20% return due to its a highly labour-intensive model. Valirx would probably need something like north of £10m revenue to generate gross profits to cover existing overheads and that’s assuming no increase in head count. 2. Stingray – So another £100k of cost and won’t know until after November 24 end of current evaluation phase. So, lets call that WIP for a year plus. No immediate cash return if ever. Then we move onto the main assets the Clinical Stage Assets: - 3. 201 – well IMO forget it, now over 14 years old and still awaiting on THX. They won’t execute the LOI but those still with faith in Suzy will need to allow it to run its course. By end of June AGM, the penny should finally drop. It’s a total dead duck. So zero revenue from here. 4. 401 – why that was handed to another business heaven knows, clearly VALs lab lacked the experience to take it inhouse but another start up with effectively an LOI that won’t get executed. So, no value here either, certainly not in the next year if ever. Then we move to pre-clinical assets: - 5. CLX – well they are spending 200k more on it and it needs another year of work plus so you will be waiting a good while on that one. It has potential IMO I like it but years off anything to deliver a financial return. 6. VAL 301 – again some of the 200k being spent on that. Its so outdated now that it will need all its IP patents revising and updating so that one is years off, if ever IMO with more cost on it but with it being 14 years old like 201 is it worth it now? Who’s knows but certainly no financial return anytime soon. 7. BC201 – no idea, was going to do something with covid a while back, missed opportunity anyhow as I see it. No follow up and badly managed like the other assets IMO. 8. AND finally we have £200k earmarked for new evaluations. Well previously they ignored new evaluations to focus on the start up lab and anything found now is at least a year away from being taken to the next stages. So no value here yet either. So, as you can see there is next to nothing here worth investing in. How they got the recent placing away at this eye watering valuation is beyond me. The entire board are culpable for the dire decisions made here and frankly they all need replacing IMO before this becomes even remotely investable. The share price will continue to drift until the changes are made. Come September they will be looking to raise again. 17 raises, three 125:1 consolidations and ZERO revenue excepting that 3 month lab contract – how have they got away with this? Unfortunately, i believe we are stuck in this limbo until the AGM when BOD positions come up for election - hopefully the change will then come. Until then IMO AVOID |
Posted at 08/12/2023 12:22 by jayj4u Great post Ron!Kings is the big fat elephant in the room no one talks about. Everyone is focused on Porky and Val 201 deal. I think once Val 201 gets done then all eyes will be on Kings and share price will rocket. Suzy would have PROVEN that she can deliever, not once but twice. Val 401 & Val 201. Kings deal could blow both Val 201 and Val 401. |
Posted at 01/12/2023 12:52 by porky9 @teamhanzLMOL You genuinely think that the two bit stateside outfit that has failed to deliver at every turn over the last few years is not only going to have this magic money pile of 60m odd to deploy to pay VAL now the initial considerations to stave off the placing but it’s also going to then go on and raise even more cash again to pay VAL another 61m on first indication. You are absolutely 100% deluded, are you for real? Think about it? VAL is about to run out of cash runway, from a business perspective even if you wanted the asset would you seriously do two raises (not that they could anyway, but let’s play the game) or would you just wait and pick up the entire VAL business for a token amount? Answers on a postcard |
Posted at 27/11/2023 05:36 by porky9 @RonPharmaYou are bringing emotion into the discussion again Its not about if you like a business or not, I like the concept of VAL i just think its a really poorly managed business and being taken in a direction that will cost shareholders significantly more time and money than it needs to. That has to change. @livedata21 Yes, the share price has recently more than doubled from 5p to 11p. I consider it VERY expensive for a business weeks away from being out of cash runway. The share price has been ramped and pumped to high heaven and there is only one direction from here and that's south. You say THX merging with EUDA represents access to NASDAQ funding overnight and that its clever financing for VAL. This is the comment i strongly disagree with:- 1. IF they merge and there is NO cash already raised and included in the deal as promised then VAL shareholders will quickly realise that the only way VAL can continue to trade in the timeline left will be with discounted placing money they will be asked to support. 2. THX is a separate legal entity to VAL. What THX do is their business. Should the merge come together but no cash included they will need to then go on and try and raise cash which has been the existing position for more than two years without success and there are no guarantees of success this time either: a) A new NASDAQ formed shell trying to raise cash would take many months with zero guarantee of success. You are asking American investors to back a start up In this market. I just don't see it happening. b) The new shell would not only be asking for significant funding BUT VALs 201 drug candidate is more than 14 years old now without any other interested parties. I'm not sure if it would stand up now under due diligence. High chance its been superseded in all that time. The market is moving towards mRNA vaccines now following the massive advances since covid that's where the small amount of smart money is going. c) If the new entity, with its new legal framework actually went onto raise cash (which it wont) then it would be well within its rights to renegotiate terms of historic LOIs. The market has changed significantly over the last two years, the new legal entity owes VAL nothing. It would have own shareholders to consider not VALs. So in all, this is still very much a binary play, for VAL to survive beyond the turn of the year either cash has to come in from THX paying them in time OR from VALs own investors via a discounted placing. I stand by my view that the share price is being ramped and pumped in order to try and secure a better placing price - we are now fast approaching D Day, i cant see the share price holding much longer. I believe VAL will have done well if they can secure support at 4p not long left to find out. Good luck |
Posted at 23/11/2023 13:35 by porky9 @LivedataI can rent lab space anywhere they are ten a penny, I could buy lab equipment out of administration or closed labs for next to FA. The value is NOT in the fixed assets it’s in the value of its profitability. You buy labs on a multiple of EBITDA. VALs lab is currently in start up, it will take a lot of time and significantly more cash to get it established. As at today, it has secured one three month external contract and the three scientists are working on own projects, not externally paying ones. Further, as I have pointed out, lab work is VERY labour intensive, the more contracts you win the more staff you need so it’s very tough to translate that into profit. It states the lab model fully in the Turner Pope report and I have commented before on this but it’s something like one scientist can generate £185k of revenue and £35k profit, can’t remember the exact figure without looking it up again but it’s along those lines hence, VAL have three scientists, currently they are working on own projects not Third Party ones so no external cash coming in. The failed business Imogen that they acquired the assets from had 33 staff at its height and still couldn’t make a profit - building a lab business takes a lot of time and effort and money. You really should do your research before trying to tell us VALs lab is worth £30m it just simply isn’t. |
Posted at 22/11/2023 23:51 by porky9 @RonPharmaYou see the merge as a positive for VAL, it's NOT. Nobody gives a flying fig. We only care if VAL will get paid or not and paid before VAL's cash runway is out at the turn of the year. 1. IF no money only a promise to go on and raise. Its no different to two years back. VAL still wont have any cash and will be coming to investors cap in hand for another hand out - discounted placing. 2. IF the two companies merge in addition to trying to raise cash they could also re-negotiate terms anyhow. I certainly would. Sorry but the placing is bolted on. THX wont pay anything ever, they wont have any cash in the new shell, just you see and frankly of i was EUDA i would avoid doing business with THX at all costs. EUDA have much much more to offer that THX and could find a much better merge partner imo. I'm just awaiting VALs resolutions for the placing and EGM data, not long to go now. |
Posted at 14/11/2023 06:28 by porky9 Time is now fast running out for VAL to sort their placing out. Most likely at the absolute eleventh hour as per previous raises.The issue now is that Anyone that wanted in on this is already in The only ones that will BUY at this ridiculous level are those working to try and hold the price up to get the discounted placing away at a better price. It won’t work but they can try. Anyone that can read an RNS and the financial statements knows the placing is bolted on. The THX merger may well happen but there wont be any cash with it, let’s face it IF they had really raised cash and had it on deposit VAL would have put out a statement to that effect already. It’s all BS to ramp the share price The share price here has been specifically ramped just for the placing. If they can get 16p they can try and place at 8p if 13p holds they can try for 6p, if 10p holds they can try for 5p BUT HNW will have non of it, too many placings and false promises. I will be impressed if Turner Pope can secure support at 4p, let’s face it, VAL have completed 15 raises, 3 125:1 consolidations, 5 raises under Suzy and 6th on the way, no revenue in 15 years other than a three month lab contract. If they can find anyone that’s not had offer of discounted shares in VAL it will be a miracle, their client bases have been well and truly rinsed frankly. As I mentioned earlier, opportunity to buy shares in a discounted Placing for VAL is as regular and common as the exclusive sales at DFS furniture. So all that will happen now is a slow drift of the share price back to 5p or a rapid fall as soon as EUDA merge and confirm no cash, only promise to try and raise as per the last couple of years. Very shortly, excluding any fluff news, next update from VAL should be details of the resolutions and the EGM date, this will be the big update with some lab stuff thrown in and confirmed indicative placing price to get the placing secured, that’s IF Turner Pope can secure the required investor support. You will likely want to remove this post also @PatientInvestor but its how it is. I stand by my call of placing at 4p to raise £800k by way of 20m share issue and we will find out shortly |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
